A Randomized Double-Blind Study Evaluating Fibrinogen-Tranexamic Acid Preventive Therapy Versus a Combined Low-Dose Regimen on Surgical Bleeding Management and Critical Care Outcomes in Patients Undergoing Radical Cystectomy
-
Alireza Shakeri
,
Mohammad Fathi
,
Parisa Sezari
,
Marzie Shahrabi
,
Maede Karimian
,
Zahra Bahramzadehharsini
,
Amin Magsudy
,
Mohsen Ariannik
,
Maryam Baniani
,
Gandom Sedehi
Abstract
Background: Radical cystectomy (RC) remains the standard of care for high-risk bladder cancer despite being associated with elevated perioperative morbidity. The procedure commonly results in substantial intraoperative blood loss, frequently requiring perioperative blood transfusions (PBT), which are associated with adverse events including transfusion-related complications and heightened healthcare expenditures. Pharmacological interventions such as tranexamic acid (TXA) and fibrinogen may decrease transfusion requirements, though TXA's potential thrombogenic effects raise safety concerns. This randomized controlled trial (RCT) aims to investigate the efficacy of combined fibrinogen and TXA delivery protocol in minimizing surgical blood loss and enhancing postoperative recovery in RC patients.
Methods: This randomized controlled trial (RCT) enrolled 140 participants scheduled for elective radical cystectomy (RC) procedures. Eligible individuals were randomly allocated to four study arms: one administered fibrinogen concentrate, a second receiving tranexamic acid (TXA), a third assigned to a lower-dose combination of both agents, and a control group receiving placebo. Primary outcomes evaluated perioperative blood loss (intraoperative and postoperative), while secondary outcomes encompased vital physiological markers and the incidence of postoperative adverse events.
Results: Patients administered fibrinogen, TXA, or a combination of both demonstrated a marked decrease in postoperative hemorrhage (1,437–1,463 mL vs. 2,727 mL in controls). Furthermore, surgical timeframes showed significant contraction in the intervention groups (4.76–4.79 hours) compared to controls (5.58 hours). These treatments were also associated with shorter hospital stays and reduced transfusion volumes of packed red blood cells and fresh frozen plasma (FFP). No statistically significant variations in acidosis or hemoglobin concentrations were observed across groups. Conversely, fibrinogen and TXA delivery protocol substantially elevated fibrinogen levels, though no clinically relevant differences emerged between the intervention patient groups.
Conclusion: The trial demonstrates that adjusting fibrinogen and TXA dosage protocols effectively reduces surgical bleeding during radical cystectomy. While combination therapy showed comparable efficacy to individual agents, these pharmacological strategies decreased transfusion dependency and hospitalization duration without increasing thromboembolic risks.
[2] Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF, et al. The Impact of Perioperative Blood Transfusion on Cancer Recurrence and Survival Following Radical Cystectomy. European Urology. 2013; 63(5):839-45.
[3] Mossanen M, Krasnow RE, Zlatev DV, Tan WS, Preston MA, Trinh QD, et al. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population‐based analysis. BJU international. 2019; 124(1):40-6.
[4] Liaw CW, Winoker JS, Wiklund P, Sfakianos J, Galsky MD, Mehrazin R. The clinical and economic burden of perioperative complications of radical cystectomy. Transl Androl Urol. 2019;8(Suppl 3):S277.
[5] Moschini M. The impact of perioperative blood transfusion on survival outcomes in radical cystectomy patients. Transl Androl Urol. 2017;6(6):1205.
[6] Siemens DR, Jaeger MT, Wei X, Vera-Badillo F, Booth CM. Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study. World J Urol. 2017; 35:1435-42.
[7] Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity‐based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010;50(4):753-65.
[8] Tan WS, Wang Y, Trinh Q-D, Preston MA, Kelly JD, Hrouda D, et al. Delayed blood transfusion is associated with mortality following radical cystectomy. Scand J Urol. 2020; 54(4):290-6.
[9] Buchner A, Grimm T, Schneevoigt B-S, Wittmann G, Kretschmer A, Jokisch F, et al. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage. Scand J Urol. 2017;51(2):130-6.
[10] Moschini M, Bianchi M, Rossi MS, Dell P, Gandaglia G, Fossati N, et al., editors. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urologic Oncology: Seminars and Original Investigations; 2016: Elsevier.
[11] Syan-Bhanvadia S, Drangsholt S, Shah S, Cai J, Miranda G, Djaladat H, et al., editors. Restrictive transfusion in radical cystectomy is safe. Urologic Oncology: Seminars and Original Investigations; 2017: Elsevier.
[12] Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999; 57(6):1005-32.
[13] Heinen A, Welke V, Behmenburg F, Stroethoff M, Stoldt V, Hoffmann T, et al. Haemotherapy with fibrinogen for perioperative bleeding prevention—a view on arterial thrombogenesis and myocardial infarction in the rat in vivo. J Clin Med. 2019; 8(6):880.
[14] Cai J, Ribkoff J, Olson S, Raghunathan V, Al‐Samkari H, DeLoughery TG, et al. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020; 104(2):79-87.
[15] Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013; 100(10):1271-9.
[16] Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther. 2015;47(4):353-64.
[17] Benipal S, Santamarina J-L, Vo L, Nishijima DK. Mortality and thrombosis in injured adults receiving tranexamic acid in the post-CRASH-2 era. West J Emerg Med. 2019; 20(3):443.
[18] Myers SP, Kutcher ME, Rosengart MR, Sperry JL, Peitzman AB, Brown JB, et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg. 2019; 86(1):20-7.
[19] Chornenki NLJ, Um KJ, Mendoza PA, Samienezhad A, Swarup V, Chai-Adisaksopha C, et al. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. Thromb Res. 2019; 179:81-6.
[20] Devereaux P, Marcucci M, Painter TW, Conen D, Lomivorotov V, Sessler DI, et al. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022; 386(21):1986-97.
[21] Solomon C, Pichlmaier U, Schoechl H, Hagl C, Raymondos K, Scheinichen D, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth. 2010; 104(5):555-62.
[22] Lupu I-M, Rebaine Z, Lhotel L, Watremez C, Eeckhoudt S, Van Dyck M, et al. A low-dose human fibrinogen is not effective in decreasing postoperative bleeding and transfusion requirements during cardiac surgery in case of concomitant clinical bleeding and low FIBTEM values: a retrospective matched study. Ann Card Anaesth. 2018;21(3):262-9.
[23] Soleimani M, Masoumi N, Nooraei N, Lashay A, Safarinejad M. The effect of fibrinogen concentrate on perioperative bleeding in transurethral resection of the prostate: a double‐blind placebo‐controlled and randomized study. J Thromb Haemost. 2017; 15(2):255-62.
[24] Waldén K, Jeppsson A, Nasic S, Backlund E, Karlsson M. Low preoperative fibrinogen plasma concentration is associated with excessive bleeding after cardiac operations. Ann Thorac Surg. 2014; 97(4):1199-206.
[25] Karlsson M, Ternström L, Hyllner M, Baghaei F, Flinck A, Skrtic S, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009;102(1):137-44.
[26] Madathil T, Balachandran R, Kottayil BP, Sundaram K, Nair SG. Comparison of efficacy of two different doses of tranexamic acid in prevention of post operative blood loss in patients with congenital cyanotic heart disease undergoing cardiac surgery. Ann Card Anaesth. 2021; 24(3):339-44.
[27] Sayadi S, Ariana S, Hosseinzadeh M, Ashari A, Yeganegi T, Memari E, et al. Efficacy of Prophylactic Intravenous Fibrinogen in Reducing Bleeding in Cesarean Section: A Randomized Controlled Trial. J Obstet Gynecol Cancer Res. 2023; 8(3):194-203.
[28] Shakeri A, Abtahi D, Shahmansouri M, Manafi-Rasi A. Prophylactic Fibrinogen Reduces Excessive Bleeding in Total Hip Arthroplasty Surgery: A Randomized Double-blinded Placebo-controlled Trial. Archives of Bone and Joint Surgery. 2023;11(8):524.
[29] Egen L, Keller K, Menold HS, Quan A, Dempfle C-E, Schoettler JJ, et al. Tranexamic acid reduces perioperative blood transfusions following open radical cystectomy–a propensity-score matched analysis. World J Urol. 2024; 42(1):1-8.
[30] Hasan MS, Yunus SN, Ng CC, Chan CYW, Chiu CK, Kwan MK. Tranexamic Acid in Pediatric Scoliosis Surgery: A Prospective Randomized Trial Comparing High-dose and Low-dose Tranexamic Acid in Adolescent Idiopathic Scoliosis Undergoing Posterior Spinal Fusion Surgery. Spine (Phila Pa 1976). 2021;46(22):E1170-e7.
[31] Goobie SM, Zurakowski D, Glotzbecker MP, McCann ME, Hedequist D, Brustowicz RM, et al. Tranexamic Acid Is Efficacious at Decreasing the Rate of Blood Loss in Adolescent Scoliosis Surgery: A Randomized Placebo-Controlled Trial. J Bone Joint Surg Am. 2018;100(23):2024-32.
[32] HALT-IT Trial Collaborators.Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020; 395(10241):1927-36.
[33] Ng KT, Yap JLL, Kwok PE. The effect of fibrinogen concentrate on postoperative blood loss: A systematic review and meta-analysis of randomized controlled trials. J Clin Anesth. 2020; 63:109782.
| Files | ||
| Issue | Article in Press |
|
| Section | Research Article(s) | |
| Keywords | ||
| Blood loss Blood transfusion Fibrinogen Hospitalization Radical cystectomy Tranexamic acid | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
